Immunotoxin Treatment of Brain Tumors
Current treatment for malignant gliomas, which includes surgery, radiation therapy, and chemotherapy, is associated with a poor prognosis (1 , 2 ). Patients with glioblastoma multiforme have an estimated 2 yr survival of less than 20% (1 ). Leptomeningeal carcinomatosis carries an estimated mean survival of 2-3 mo (3 ). Localized radiation therapy techniques such as brachytherapy and stereotactic radiosurgery often fail to prevent disease progression at the primary tumor site (4 ). Unfortunately, the lack of specificity of both radiation therapy and chemotherapy for malignant cells has resulted in central nervous system (CNS) toxicity and unacceptable side effects (1 , 2 ).
- 主要组织相容性复合体
- 改良过碘酸钠标记法制备酶标抗体
- 抗胞内病毒感染免疫
- 抗体产生的一般规律
- Purification of Antibodies Using Ammonium Sulfate Fractionation or Gel Filtration
- Protein-Polysaccharide Conjugation
- Methods for In Vivo Analyses of Natural Killer (NK) Cells
- Immunoprivileged Sites: The Testis
- Class-Specific Effector Functions of Therapeutic Antibodies
- Biochemical Large-Scale Identification of MHC Class I Ligands